Topiramate pharmacokinetics in children with epilepsy aged from 6 months to 4 years

Area of Science:

• Pharmacology
• Pediatric Neurology
• Clinical Pharmacy

Background:

• Topiramate (TPM) is an antiepileptic drug (AED) used in pediatric epilepsy.
• Drug interactions with concomitant AEDs can alter TPM pharmacokinetics, especially in young children.
• Understanding these interactions is crucial for optimizing treatment efficacy and safety.

Purpose of the Study:

• To investigate the steady-state pharmacokinetics of topiramate (TPM) in children under 4 years old.
• To evaluate the impact of comedication with different classes of antiepileptic drugs (AEDs) on TPM pharmacokinetics.
• To determine optimal dosing strategies for TPM in this vulnerable pediatric population.

Main Methods:

• An open-label prospective study involving 22 children (6 months to 4 years) with pharmacoresistant epilepsy.
• Participants were grouped based on comedication: enzyme-inducing AEDs, valproic acid (VPA), or neutral AEDs.
• Plasma TPM concentrations were measured at multiple time points post-dose to determine pharmacokinetic parameters using a noncompartmental method.

Main Results:

• Apparent oral clearance (CL/F) of TPM was significantly higher in children receiving enzyme-inducing AEDs compared to those on VPA or neutral AEDs.
• Dose-normalized area under the plasma concentration-time curve (AUC) for TPM was significantly lower in patients on enzyme-inducing AEDs.
• These findings indicate faster elimination of TPM when co-administered with enzyme-inducing AEDs.

Conclusions:

• Children under 4 years on enzyme-inducing AEDs require higher TPM doses (mg/kg) to reach comparable plasma concentrations.
• Concomitant enzyme-inducing AEDs significantly increase TPM clearance in young children.
• This highlights the importance of individualized dosing and therapeutic drug monitoring for TPM in pediatric epilepsy management.